Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Stefan Blankenberg, Moritz Seiffert, Reinhard Vonthein, Helmut Baumgartner, Sabine Bleiziffer, Michael A Borger, Yeong-Hoon Choi, Peter Clemmensen, Jochen Cremer, Martin Czerny, Nina Diercks, Ingo Eitel, Stephan Ensminger, Derk Frank, Norbert Frey, Andreas Hagendorff, Christian Hagl, Christian Hamm, Utz Kappert, Matthias Karck, Won-Keun Kim, Inke R König, Markus Krane, Ulf Landmesser, Axel Linke, Lars S Maier, Steffen Massberg, Franz-Josef Neumann, Hermann Reichenspurner, Tanja K Rudolph, Christof Schmid, Holger Thiele, Raphael Twerenbold, Thomas Walther, Dirk Westermann, Erion Xhepa, Andreas Ziegler, Volkmar Falk
BACKGROUND: Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice. METHODS: In this randomized noninferiority trial conducted at 38 sites in Germany, we assigned patients with severe aortic stenosis who were at low or intermediate surgical risk to undergo either TAVI or SAVR...
April 8, 2024: New England Journal of Medicine
#22
Symon Reza, Brandon Kovarovic, Danny Bluestein
Transcatheter aortic valve replacement (TAVR) has rapidly displaced surgical aortic valve replacement (SAVR). However, certain post-TAVR complications persist, with cardiac conduction abnormalities (CCA) being one of the major ones. The elevated pressure exerted by the TAVR stent onto the conduction fibers situated between the aortic annulus and the His bundle, in proximity to the atrioventricular (AV) node, may disrupt the cardiac conduction leading to the emergence of CCA. In his study, an in-silico framework was developed to assess the CCA risk, incorporating the effect of a dynamic beating heart and pre-procedural parameters such as implantation depth and preexisting cardiac asynchrony in the new onset of post-TAVR CCA...
March 29, 2024: medRxiv
#23
JOURNAL ARTICLE
Julius Jelisejevas, François Regoli, Daniel Hofer, Giulio Conte, Tardu Oezkartal, Ardan M Saguner, Maria Luce Caputo, Lorenzo Grazioli, Jan Steffel, Angelo Auricchio, Alexander Breitenstein
BACKGROUND: Impairment of the conduction system is a common complication of transcatheter aortic valve replacement (TAVR), which is typically performed in elderly patients. A leadless pacemaker (LP) may be a suitable option in this frail population, but the available scientific data concerning the efficacy and safety of leadless pacing after TAVR are sparse. The purpose of this analysis was to evaluate the efficacy and safety of LP implantation in patients with relevant bradycardias after TAVR, compared to other indications...
February 2024: CJC open
#24
JOURNAL ARTICLE
Jonathon B Ryan, Peter W Grant
BACKGROUND: Transcatheter aortic valve implantation (TAVI) did not receive regulatory approval in Australia until 2013, several years after Europe (2007) and America (2011). Consequently, the uptake of TAVI in Australia initially lagged behind international best practices. This study was undertaken to provide an update on the status of TAVI activity in Australia. METHOD: A descriptive population-level epidemiological study was performed. Annual activity data for both surgical aortic valve replacement (SAVR) and TAVI were obtained from the Australian Institute of Health and Welfare (AIHW) for the period from 1 July 2012 to 30 June 2022...
April 6, 2024: Heart, Lung & Circulation
#25
JOURNAL ARTICLE
Emma K Gard, Samer Noaman, Dion Stub, Pieter Vriesendorp, Nay Htun, Rozanne Johnston, Elisha Gartner, Ronald Dick, Antony Walton, David Kaye, Shane Nanayakkara
BACKGROUND: Patients undergoing transcatheter aortic valve implantation (TAVI) have a high comorbidity burden. We sought to stratify patients into functional outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ-12), a patient-reported outcome with benefits over both the New York Heart Association (NYHA) classification and the original 23-item KCCQ, and to evaluate the importance of comorbidities in predicting failure of functional improvement post-TAVI in a contemporary cohort...
April 5, 2024: Heart, Lung & Circulation
#26
JOURNAL ARTICLE
Md Shajedur Rahman Shawon, Jonathon B Ryan, Louisa Jorm
BACKGROUND: In Australia, transcatheter aortic valve implantation (TAVI) is only performed in a limited number of specialised metropolitan centres, many of which are private hospitals, making it likely that TAVI patients who require readmission will present to another (non-index) hospital. It is important to understand the impact of non-index readmission on patient outcomes and healthcare resource utilisation. METHOD: We analysed linked hospital and death records for residents of New South Wales, Australia, aged ≥18 years, who had an emergency readmission within 90 days following a TAVI procedure in 2013-2022...
April 4, 2024: Heart, Lung & Circulation
#27
JOURNAL ARTICLE
Hiroshi Onoda, Teruhiko Imamura, Hiroshi Ueno, Akira Oshima, Ryuichi Ushijima, Mitsuo Sobajima, Koichiro Kinugawa
BACKGROUND: Aortic valve replacement is recommended for patients with "very severe" aortic stenosis (AS), irrespective of symptomatic manifestation. Nonetheless, the prognostic ramifications of "very severe" AS, as opposed to "severe" AS, subsequent to trans-catheter aortic valve implantation (TAVI) remain enigmatic. METHODS: We enrolled consecutive patients who received TAVI at our institute between May 2015 and April 2021. We scrutinized the impact of baseline "very severe" AS upon 3-year all-cause death or heart failure hospitalization following TAVI, in comparison to "severe" AS...
April 3, 2024: Journal of Cardiology
#28
EDITORIAL
Sudesh Prajapathi, Akshyaya Pradhan
Several anatomical, demographic, clinical, electrocardiographic, procedural, and valve-related variables can be used to predict the probability of developing conduction abnormalities after transcatheter aortic valve replacement (TAVR) that necessitate permanent pacemaker (PPM) implantation. These variables include calcifications around the device landing zone and in the mitral annulus; pre-existing electrocardiographic abnormalities such as left and right bundle branch blocks (BBB), first- and second-degree atrioventricular blocks, as well as bifascicular and trifascicular blocks; male sex; diabetes mellitus (DM); hypertension; history of atrial fibrillation; renal failure; dementia; and use of self-expanding valves...
March 26, 2024: World Journal of Cardiology
#29
Kanna Nakamura, Yasushi Fuku, Kazushige Kadota
No abstract text is available yet for this article.
April 2024: European Heart Journal. Case Reports
#30
REVIEW
Thomas J Stocker, Jörg Hausleiter
Tricuspid regurgitation (TR) leading to right heart failure is prevalent and associated with increased mortality. The significant under-recognition of the disease resulted from insufficient medical therapies and the high associated risk of surgical therapy. Over the last decade there has been a rapid development of interventional treatment options so that the disease has increasingly become the focus of attention of specialists in internal medicine and interventional cardiologists. The etiology of TR is differentiated into primary TR, secondary atrial TR, secondary ventricular TR and TR associated with cardiac implantable electronic devices (CIED)...
April 3, 2024: Inn Med (Heidelb)
#31
JOURNAL ARTICLE
Priyanka Gera, David Haner Wasserstein, William H Frishman, Wilbert S Aronow
Aortic regurgitation (AR), a left-sided valvular heart disease, poses challenges in both diagnosis and treatment. From rheumatic fever to trauma, the vast etiologies of AR can manifest with varying symptoms and disease progression. Nonetheless, without interventions, patients with acute and chronic symptomatic AR have a poor prognosis. This article synthesizes current knowledge on AR management, emphasizing advancements in transcatheter aortic valve implantation (TAVI). While surgical aortic valve replacement remains the gold standard, TAVI has emerged as a promising alternative, particularly for inoperable patients...
April 3, 2024: Cardiology in Review
#32
JOURNAL ARTICLE
Derk Frank, Eric Durand, Sandra Lauck, Douglas F Muir, Mark Spence, Mariuca Vasa-Nicotera, David Wood, Francesco Saia, Cristóbal A Urbano-Carrillo, Damien Bouchayer, Vlad Anton Iliescu, Christophe Saint Etienne, Florence Leclercq, Vincent Auffret, Lluis Asmarats, Carlo Di Mario, Aurelie Veugeois, Jiri Maly, Andreas Schober, Luis Nombela-Franco, Nikos Werner, Joan Antoni Gómez-Hospital, Julia Mascherbauer, Giuseppe Musumeci, Nicolas Meneveau, Thibaud Meurice, Felix Mahfoud, Federico De Marco, Tim Seidler, Florian Leuschner, Patrick Joly, Jean-Philippe Collet, Ferdinand Vogt, Emilio Di Lorenzo, Elmar Kuhn, Vicente Peral Disdier, Violetta Hachaturyan, Claudia M Lüske, Radka Rakova, Wilbert Wesselink, Jana Kurucova, Peter Bramlage, Gemma McCalmont
BACKGROUND AND AIMS: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. METHODS: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices...
March 30, 2024: European Heart Journal
#33
JOURNAL ARTICLE
Safi U Khan, Sourbha S Dani, Sarju Ganatra, Talha Ahmed, Amro Agalan, Sumanth Khadke, Siddharth Agarwal, Syed Zaid, Hassaan B Arshad, Salman Zahid, Alpesh R Shah, Sachin S Goel, Neal S Kleiman
BACKGROUND: The role of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) who subsequently undergo transcatheter aortic valve replacement (TAVR) remains uncertain. Therefore, we conducted this study to assess the association of PCI before TAVR with mortality and cardiovascular outcomes. METHODS: We used the TriNetX database (Jan 2012 - Aug 2022) and grouped patients into PCI (3 months or less) before TAVR and no PCI...
March 22, 2024: Cardiovascular Revascularization Medicine: Including Molecular Interventions
#34
JOURNAL ARTICLE
John E Connolly, Howard C Herrmann, Pavan Atluri, Nimesh Desai, Paul N Fiorilli, Jay Giri, Robert H Li, Taisei Kobayashi, Ashwin S Nathan, Wilson Y Szeto, Joshua C Grimm
BACKGROUND: Studies comparing transcatheter and surgical aortic valve replacement (TAVR and SAVR) for patients with trileaflet aortic stenosis (AS) have found similar or larger effective orifice area (EOA) for TAVR prostheses. To our knowledge, no studies have compared EOA in patients undergoing TAVR versus SAVR for bicuspid AS. METHODS: We retrospectively compared prosthetic valvular sizing and predicted EOA for patients with bicuspid AS undergoing TAVR or SAVR at our institution between January 1, 2016, and December 31, 2021...
March 21, 2024: Cardiovascular Revascularization Medicine: Including Molecular Interventions
#35
JOURNAL ARTICLE
Sameer Kurmani, Bhavik Modi, Aditya Mukherjee, David Adlam, Amerjeet Banning, Andrew Ladwiniec, Raj Rajendra, Julia Baron, Elved Roberts, Andre Ng, Iain Squire, Gerald McCann, Nilesh J Samani, Jan Kovac
BACKGROUND: Aortic stenosis is a life-limiting condition for which transcatheter aortic valve implantation (TAVI) is an established therapy. Coronary artery disease (CAD) is frequently found in this patient group and optimal management in these patients remains uncertain. OBJECTIVES: We sought to examine the association of coexistent CAD on mortality and hospital readmission in patients undergoing TAVI. METHODS: In this observational cohort study, we examined patients who underwent TAVI and segregated them by the presence of obstructive epicardial CAD...
March 29, 2024: Open Heart
#36
JOURNAL ARTICLE
Torsten P Vahl, Vinod H Thourani, Raj R Makkar, Nadira Hamid, Omar K Khalique, David Daniels, James M McCabe, Lowell Satler, Mark Russo, Wen Cheng, Isaac George, Gabriel Aldea, Brett Sheridan, Dean Kereiakes, Harsh Golwala, Firas Zahr, Stanley Chetcuti, Pradeep Yadav, Susheel K Kodali, Hendrik Treede, Stephan Baldus, Nicholas Amoroso, Lauren S Ranard, Duane S Pinto, Martin B Leon
BACKGROUND: Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients...
March 26, 2024: Lancet
#37
JOURNAL ARTICLE
Mahmoud Baraka, Diaa Kamal, Ahmad E Mostafa
BACKGROUND: Conduction disturbances remain one of the most common complications occurring post TAVI. We aim to determine the predictors of cardiac conduction disturbances after Transcatheter Aortic Valve Implantation (TAVI) and propose a relevant predictive model. We included 70 consecutive patients with severe symptomatic AS who underwent TAVI using the self-expanding valve Evolut R or the balloon expandable Sapien XT valve. All patients were subjected to electrocardiographic evaluation pre- and post-TAVI and at 30 days...
March 26, 2024: Indian Pacing and Electrophysiology Journal
#38
JOURNAL ARTICLE
Andrea Papa, Teodor Serban, Ivo Strebel, Sven Knecht, Corinne Isenegger, Thomas Nestelberger, Christoph Kaiser, Gregor Leibundgut, Philipp Haaf, Beat Schaer, Philipp Krisai, Stefan Osswald, Christian Sticherling, Michael Kühne, Patrick Badertscher
BACKGROUND: Infranodal conduction disorders are common after transcatheter aortic valve replacement (TAVR). Risk factors are incompletely understood. OBJECTIVE: The purpose of this study was to assess the impact of valve implantation depth and calcium burden of the device landing zone on infranodal conduction intraprocedure pre- and post-TAVR. METHODS: In all patients undergoing TAVR between June 2020 and June 2021, the His-ventricle (HV) interval was measured pre- and post-valve deployment...
February 2024: Heart rhythm O2
#39
JOURNAL ARTICLE
Richard Tanner, Daniele Giacoppo, Hassan Saber, David Barton, Declan Sugrue, Andrew Roy, Gavin Blake, Mark S Spence, Ronan Margey, Ivan P Casserly
OBJECTIVE: A paucity of data exists on how transcatheter aortic valve implantation (TAVI) practice has evolved in Ireland. This study sought to analyse temporal trends in patient demographics, procedural characteristics, and clinical outcomes at an Irish tertiary referral centre. METHODS: The prospective Mater TAVI database was divided into time tertiles based on when TAVI was performed: Group A, November 2008-April 2013; Group B, April 2013-September 2017; and Group C, September 2017-February 2022...
March 27, 2024: Open Heart
#40
JOURNAL ARTICLE
Camille Sarrazyn, Xavier Galloo, Maria Chiara Meucci, Steele C Butcher, Kensuke Hirsawa, Rinchyenkhand Myagmardorj, Frank van der Kley, Tine De Backer, Jeroen J Bax, Nina Ajmone Marsan
(1) Background: Left ventricular global longitudinal (LVGLS) and right ventricular free wall strain (RVFWS) demonstrated separate prognostic values in patients with severe aortic stenosis (AS). However, studies evaluating the combined assessment of LVGLS and RVFWS have shown contradictory results. This study explored the prognostic value of combining LVGLS and RVFWS in a large group of severe AS patients referred for transcatheter aortic valve implantation. (2) Methods: Patients were classified into three groups: preserved (LVGLS ≥ 15% AND RVFWS > 20%), single-ventricle impaired (LVGLS < 15% OR RVFWS ≤ 20%), or biventricular-impaired strain group (LVGLS < 15% AND RVFWS ≤ 20%)...
March 13, 2024: Journal of Cardiovascular Development and Disease
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
